Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.0842
-0.0008 (-0.94%)
At close: May 13, 2026, 4:00 PM EDT
0.0794
-0.0048 (-5.70%)
After-hours: May 13, 2026, 7:58 PM EDT
Aditxt Revenue
In the year 2025, Aditxt had annual revenue of $3.20K, down -97.62%. Aditxt had revenue of $425.00 in the quarter ending December 31, 2025, a decrease of -86.61%.
Revenue (ttm)
$3.20K
Revenue Growth
-97.62%
P/S Ratio
23.84
Revenue / Employee
$123
Employees
26
Market Cap
76.16K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.20K | -130.79K | -97.62% |
| Dec 31, 2024 | 133.99K | -511.19K | -79.23% |
| Dec 31, 2023 | 645.18K | -288.54K | -30.90% |
| Dec 31, 2022 | 933.72K | 828.68K | 788.96% |
| Dec 31, 2021 | 105.03K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.51M |
| Scinai Immunotherapeutics | 1.31M |
| Onconetix | 815.37K |
| AIM ImmunoTech | 88.00K |
| HCW Biologics | 54.23K |
| Aspire Biopharma Holdings | 6.20K |
ADTX News
- 23 days ago - Aditxt announces publication featuring Ignite Proteomics subsidiary - TheFly
- 23 days ago - Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients - Business Wire
- 4 weeks ago - Aditxt files to sell 148.28M shares of common stock for holders - TheFly
- 7 weeks ago - Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer - Business Wire
- 2 months ago - Aditxt acquires Ignite Proteomics in $36M transaction - TheFly
- 2 months ago - Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection - Business Wire
- 2 months ago - Aditxt to effect 1-for-8 reverse split of common stock - TheFly
- 2 months ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026 - Business Wire